For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Cardiovascular Research Institute

You are here

Concise Review: Application of Chemically Modified mRNA in Cell Fate Conversion and Tissue Engineering.

TitleConcise Review: Application of Chemically Modified mRNA in Cell Fate Conversion and Tissue Engineering.
Publication TypeJournal Article
Year of Publication2019
AuthorsBadieyan, ZSadat, Evans, T
JournalStem Cells Transl Med
Date Published2019 Mar 19

Chemically modified RNA (cmRNA) has potential as a safe and efficient tool for nucleic acid-based therapies and regenerative medicine. Modifications in the chemistry of mRNA can enhance stability, reduce immunogenicity, and thus facilitate mRNA-based nucleic acid therapy, which eliminates risk of insertional mutagenesis. In addition to these valuable advantages, the mRNA-based method showed significantly higher efficacy for reprogramming somatic cells to pluripotency compared with DNA- or protein-based methods. These findings suggest cmRNA can provide a powerful and safe tool for cell programming and reprogramming. Delivery methods, particularly using lipid nanoparticles, provide strategies for cell and organ-specific targeting. The present study comprehensively compares studies that have used cmRNAs for cell fate conversion and tissue engineering. The information should be useful for investigators looking to choose the most efficient and straightforward cmRNA-based strategy and protocol for tissue engineering and regenerative medicine research. Stem Cells Translational Medicine 2019.

Alternate JournalStem Cells Transl Med
PubMed ID30891922
Grant ListNYSTEM C32558GG / / New York State Department of Health /
NYSTEM C32591GG and C32593GG / / New York State Department of Health /
R35-HL135778 / / National Institutes of Health /
W81XWH-17-1-0661 / / Department of Defense /
18CSA34080171 / / American Heart Association /
2016-004 / / Tri-Institutional Stem Cell Initiative /
2016-032 / / Tri-Institutional Stem Cell Initiative /